News

MNM Bioscience eyes cancer drug target discovery based on its AI algorithms

Date
April 15, 2022
No items found.

MNM Bioscience began as a bioinformatics company that curates data and then builds artificial intelligence-based algorithms, but it is now looking to branch out into oncology drug target discovery.

About six months ago, management had what he called a “revelation” that the firm could work in this new realm because MNM discovered that about 30 percent of patients with triple-negative breast cancer had tumors with a unique genomic signature.

MNM Bioscience eyes cancer drug target discovery based on its AI algorithms
June 23, 2022

You may also like

“Random similarity forests” has been accepted at ECML PKDD 2022

We are very happy to announce that our abstract and related publication titled “Random similarity forests” has been accepted at this year’s European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases- #ECMLPKDD2022!

MNM Bioscience announced that it had filed a provisional patent application

MNM Bioscience announced that it had filed a provisional patent application

MNM at the ESMO 2022 Congress

At ESMO 2022 Congress in Paris the era of AI deployment continues.

Europe Biobank Week 2021

Almost a week has passed since the Europe Biobank Week 2021, and yet we are still impressed! We have attended great lectures, in which the speakers approached the topic of biobanking from different perspectives.